State psychedelics legalization and policy roundup — June 2025

This post is part of an ongoing series summarizing state-based psychedelic reforms intended for policy professionals.

Arizona

Arizona Senate Bill 1555, by state Sen. T.J. Shope (R-16), would have authorized a regulated market for psilocybin-assisted therapy. However, the bill was heavily amended and pared down to legalize a pharmaceutical version of synthetic psilocybin, conditional upon its approval by the Food and Drug Administration (FDA). The bill passed the Arizona Senate but never received a floor vote in the House.

California

California Senate Bill 751, introduced by state Sen. Josh Becker (D-13), would have established a pilot program allowing veterans and first responders to receive psilocybin treatment. California lawmakers have made several attempts to regulate or legalize psychedelics, including a 2023 bill that Gov. Gavin Newsom ultimately vetoed.

This new proposal shifted the focus toward therapy, granting the University of California system authority to train therapists and gather research, aligning with the governor’s call for a more “therapeutic” framework. (Read more about Reason Foundation’s recommendations here.)

The bill died in committee on May 23.

Colorado

Colorado Senate Bill 297 (multiple sponsors) would allow the governor to grant clemency to those convicted of offences related to psychedelic drugs, such as psilocybin, that the state has subsequently legalized through Ballot Measure 122. The bill would also require the state to collect data on public health outcomes, such as hospital discharge data related to psychedelics.

Gov. Jared Polis signed the bill on June 3. Healing centers (organizations that administer psychedelic sessions) are required to send information on sessions by July 1, 2026.

Connecticut

Connecticut House Bill 7065 (introduced through the House Judiciary Committee) would remove jail time for personal possession of up to half an ounce of psilocybin. The first offense would be a $150 fine. The bill has passed the Connecticut House of Representatives and was placed on the Senate calendar for consideration, but there was no further recorded action before the legislature adjourned for the 2025 session.

Florida

Florida House Bill 651 criminalizes the sale and distribution of spores capable of producing psilocybin. While psilocybin is a controlled substance, many states do not have laws explicitly banning the “seeds” of mushrooms that, once cultivated, become potent with psychedelic compounds. In this case, providers may not sell spores and cultivation kits. Florida Gov. Ron DeSantis signed the bill into law on May 15. It will go into effect in July.

Iowa

Iowa House Bill 383, put forth by the Senate Health and Human Services Committee, would legalize a pharmaceutical version of synthetic psilocybin, conditional upon its approval by the FDA. It was sent to Gov. Kim Reynolds for her signature on May 19, but she vetoed the bill.

House Bill 620, sponsored by state Rep. John Wills (R-10), would have authorized a psilocybin facilitated-access program for individuals suffering from a range of mental health conditions. The Iowa House approved it on an 84-6 vote in April, but the bill did not receive a floor vote in the Iowa Senate prior to the legislature’s conclusion.

Illinois

Illinois Senate Bill 2184, from state Sen. Rachel Ventura (D-43), is the companion bill to House Bill 1143, sponsored by state Rep. LaShawn Ford (D-8). It would allow a regulated market for professional psilocybin services. As noted in a previous state roundup, individuals would not need a mental illness diagnosis to gain access. However, it failed to secure full Senate approval before the legislature adjourned.

Hawaii

Hawaii Senate Bill 1042 by state Sen. Chris Lee (D-32) would establish a pilot program to study psychedelic therapies, including those using MDMA and psilocybin. The proposal was transmitted from the Hawaii House to the Senate; the bill received a conference committee hearing on April 25 and has not yet been scheduled for another hearing. 

Maine

House Bill 1034 (multiple sponsors) would decriminalize the personal possession of psilocybin. The state website says the measure received a “divided” committee vote from the House Committee on Criminal Justice and Public Safety, with members disagreeing about whether it should pass as is, as amended, or not pass at all. On June 4, it was tabled in the House without a plan to discuss when it would be considered.

Massachusetts

House Bill 4050 (previously known as House Docket 1003), from state Rep. Patrick Joseph Kearney (D-4), would authorize a regulated psilocybin market in which individuals could acquire purchase licenses for at-home consumption and gifting would be allowed between license holders. It was referred to the Committee on Revenue on April 22.

Missouri

House Bill 951, from state Rep. Matthew Overcast (R-155), would authorize a medicalized framework to access psilocybin-assisted therapy for patients suffering from certain specified conditions, including terminal illness, major depressive disorder, or post-traumatic stress disorder (PTSD). It did not receive a committee hearing prior to the legislature’s adjournment on May 16.

New Hampshire

House Bill 528 from state Rep. Kevin Verville (R-Rockingham) would reduce penalties for the possession of psilocybin. It has been amended to include severe penalties, including minimum jail time, for individuals who knowingly traffic large amounts of fentanyl. Verville told Marijuana Moment the amendment, which he did not initiate, is a fair compromise if it means the bill can pass. It was laid on the table by the Senate on June 5, pending a committee amendment. There are no reported plans to advance the bill before the legislature adjourns in June.

New Mexico

Senate Bill 219  (multiple sponsors) became the first state legislative measure related to the legalization of psychedelics to receive a governor’s signature and become law. All preceding state legalization measures were enacted by citizen initiative. This bill will allow qualifying patients to be seen by a licensed medical practitioner under a regulated system. Unlike regulations developed in other states, the bill does not specify a minimum number of hours of training that are required to administer psychedelics but instead gives the government broad discretion to determine “necessary initial and ongoing training for producers and clinicians.” The Department of Health is required to implement the program by 2027.

Oregon

Oregon House Bill 2387, from state Rep. Dacia Grayber (D-28), modifies Oregon’s psilocybin laws. One major provision prevents medical license holders from being disciplined by certain medical boards for providing psilocybin services, aligning Oregon with Colorado by allowing both medical and non-medical professional facilitators. Gov. Tina Kotek signed the bill on May 23. The portion of the bill related to clinical facilitators takes effect on January 1, 2026. The bill contains other provisions, such as keeping confidential investigations into abuse by a licensed facilitator center. These provisions took effect immediately on passage.

House Bill 3817 (multiple sponsors) would authorize a medical market offering treatment with ibogaine. Details about how the program would be administered and its timeline are left up to interpretation by the state departments for health and veterans’ affairs. The bill doesn’t specify how the state would acquire ibogaine. Its naturally occurring source, the iboga shrub, does not natively grow in Oregon. It could potentially require an import license from the federal government or the local manufacture of a synthetic version. On April 16, it was referred to the Ways and Means Committee. There is no indication that the bill will progress or be rejected before Oregon adjourns in June.

Senate Bill 907 (multiple sponsors) makes technical changes to disclosure requirements regarding the physical locations of individuals seeking to grow psilocybin. Among the reforms is a requirement that candidate psilocybin manufacturers disclose the address and the owner of the growing facility in their application to the state health authority. The governor signed the bill on May 28. This provision goes into effect January 1, 2026.

Texas

Senate Bill 2308 appropriates the funding for clinical trials into potential pharmaceutical applications of the psychedelic compound ibogaine. The bill authorizes the disbursement of $50 million in grants to recipients capable of conducting FDA-supervised trials. Read Reason Foundation’s testimony in favor of the bill here. Gov. Greg Abbott signed the bill on June 11.

Virginia

Senate Bill 1135, from State Sen. Jennifer Boysko (D-District 33), proposed to authorize a pharmaceutical analog of psilocybin contingent upon approval by the FDA. It was vetoed by Gov. Glenn Youngkin on April 2. The veto letter noted, “This legislation is premature to the appropriate FDA approval and DEA drug scheduling. No other drugs are anachronistically codified by the state before federal approval.”

Summary

As was the case in 2024, most good psychedelics reforms introduced during the 2025 state legislative sessions did not pass.

However, 2025 saw a few notable wins, such as legalizing a regulated market in New Mexico and funding for Ibogaine research in Texas. Perhaps 2026 will be a year with even more impactful legislation.

The post State psychedelics legalization and policy roundup — June 2025 appeared first on Reason Foundation.

Source: https://reason.org/commentary/state-psychedelics-legalization-and-policy-roundup-june-2025/